Skip to main
BAX

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International's stock outlook is supported by positive sales growth in its Healthcare Systems & Technologies segment, which reported increases of approximately 6% and 2% year-over-year in the first and second quarters of 2025, respectively. The company has strategically expanded its product offerings through the acquisition of Hillrom, which enhances its competitive positioning in the healthcare market by adding essential hospital equipment. Additionally, management indicated that pricing initiatives are expected to contribute a one-time sales growth benefit of about 100 basis points in 2024 and 2025, further strengthening the financial outlook for the company.

Bears say

Baxter International's financial performance in the second quarter of 2025 was marked by below-consensus results in sales, gross margins, and earnings per share, indicating ongoing challenges in operational efficiency. The company has faced a tumultuous period from 2021 to 2023, characterized by several operational missteps that have resulted in inconsistent quarterly performances and negative revisions to future guidance. Furthermore, the reported gross margins of 40.7% and operating margins of 15.1% both fell short of consensus estimates, reflecting significant sales softness and unfavorable manufacturing conditions.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.